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Abstract 
Background: Methylation of DNA at CpG sites is an epigenetic modification and a potential modifier of disease risk, 
possibly mediating environmental effects. Currently, DNA methylation is commonly assessed using specific microar-
rays that sample methylation at a few % of all methylated sites.
Methods: To understand if significant information on methylation can be added by a more comprehensive analysis 
of methylation, we set up a quantitative method, bisulfite oligonucleotide-selective sequencing (Bs-OS-seq), and 
compared the data with microarray-derived methylation data. We assessed methylation at two asthma-associated 
genes, IL13 and ORMDL3, in blood samples collected from children with and without asthma and fractionated white 
blood cell types from healthy adult controls.
Results: Our results show that Bs-OS-seq can uncover vast amounts of methylation variation not detected by com-
monly used array methods. We found that high-density methylation information from even one gene can delineate 
the main white blood cell lineages.
Conclusions: We conclude that high-resolution methylation studies can yield clinically important information at 
selected specific loci missed by array-based methods, with potential implications for future studies of methylation-
disease associations.
Keywords: Asthma, Bs-OS-sequencing, CpG sites, DNA methylation, Epigenetic profiling, IL13, ORMDL3, 450 k
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
DNA methylation as an epigenetic marker has gained 
popularity in assessing the role of potential environ-
mental modifiers in disease pathogenesis, leading to the 
emergence of the concept Epigenome-Wide Association 
Studies (EWAS). The popularity of this approach has 
been facilitated by the ease of analyzing genome-wide 
methylation patterns using microarrays, such as the 
Illumina’s 450k and EPIC arrays, containing probes for 
450,000 and 850,000 potentially methylated CpG sites, 
respectively [1, 2]. The approach suffers, however, from 
two main problems. First, the number of methylation-
susceptible CpG sites in the genome is nearly 30 mil-
lion, and thus even the EPIC array addresses fewer than 
3% of these CpG sites. Second, while single-nucleotide 
polymorphisms (SNPs) at nearby sites are often in link-
age disequilibrium, and thus their alleles can be reliably 
predicted by nearby markers’ alleles, the same does not 
seem to hold true for methylation patterns. Another 
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complicating factor is that the importance of methyla-
tion at specific sites or regions of the genome is still not 
fully understood, and much biologically important varia-
tion may remain undisclosed with array-based methods. 
The distribution of CpG sites within the arrays is biased 
towards the CpG island with very few CpG sites scattered 
within the CpG island shores and the gene body, gene 
locations with remarkable effects on epigenetic regula-
tion. Also, methylation patterns vary by cell type, and 
even nearby methylated sites can vary in different cell 
types dependent on their functional role, and even over 
time [3]. Thus, in any epigenetic methylation study there 
is a risk of potentially missing a large body of informa-
tion, but exactly how much, is typically not assessed. To 
achieve full methylation pattern coverage, one can apply, 
e.g., bisulfite sequencing of the entire genome, though the 
high cost involved obviously limits its use in large studies.
We had two aims for the current study. First, we set 
out to design an assay that is targeted, quantitative, and 
at a reasonably low cost to assess full methylation pat-
terns in targeted regions of the genome, such as genes 
considered especially interesting for a certain analysis. 
Second, we wanted to assess the amount of addition-
ally gained information by comparing the new method 
to data obtained from the same DNA samples using the 
Illumina 450  K microarray [4, 5]. The novel method, 
Bisulfite Oligonucleotide-selective sequencing (Bs-OS-
seq), is based on the targeted capture of CpG sites using 
specific oligonucleotides across the region of interest 
followed by deep sequencing of the captured DNA mol-
ecules after bisulfite conversion. The process yields a 
mixed population of variant sequences depending on 
the level of methylation at any given position (Fig. 1). In 
an attempt to validate this new method, we analyzed the 
methylation profiles of the IL13 and ORMDL3 genes, as 
they have both been implicated in asthma [6], represent-
ing the involvement of different cell types, and are there-
fore interesting targets to understand the variation of 
methylation as a factor possibly contributing to asthma 
pathogenesis.
Results
We analyzed DNA methylation patterns in two sets of 
samples with the new bs-OS-seq method for methylation 
analysis to assess the level of variation and the increase of 
information as compared to the reference Illumina 450k 
array data (Fig. 2), in the two asthma-related genes IL13 
and ORMDL3. One sample set consisted of sorted blood 
cell populations (CD4 + T cells, CD8 + T-cells, CD19 + B 
cells, CD14 + monocytes, granulocytes, and neutrophils) 
and PBMCs from 6 healthy adult male blood donors, 
and one set consisted of whole blood samples from 22 
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Fig. 1 A schematic description of the Bisulfite Oligonucleotide-Selective sequencing (Bs-OS-seq) method
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school-aged asthmatic children and age-matched healthy 
controls.
Targeted bs‑OS‑Seq identifies methylation patterns 
in higher resolution compared to Illumina 450k microarray 
in PBMCs of healthy adult males
We analyzed DNA methylation patterns in the CpG 
islands and shores of the genes IL13 and ORMDL3, with 
bs-OS-Seq in a sample set of PBMCs from 6 healthy 
adult male donors [4, 7] to assess the level of agreement 
between the methods and the increase of information 
with bs-OS-Seq as compared to the reference Illumina 
450k array data from the same data set (Fig.  2). The 
dense data set obtained with bs-OS-seq reveal a much 
richer pattern of methylation variation across the stud-
ied loci than is evident in the 450k array data (Fig.  2a), 
with 268 versus 14 CpG sites in IL13, and 259 versus 17 
CpG sites in ORMDL3. Hypomethylation was seen in the 
CpG island while higher methylation levels were seen 
in the surrounding CpG sites. Comparison of methyla-
tion measurements between the two methods demon-
strated a high level of agreement at the 14 (IL13) and 
17 (ORMDL3) overlapping CpG-sites, with correlation 
scores ranging from 0.856 to 0.971 (Fig.  2b, Table  1, 
Additional file 1:  Fig. 1).
Next, we analyzed the extent of methylation variation 
over the two regions revealing that among the top 10% of 
most varying methylation sites by bs-OS-seq, only 3 and 
1 sites in IL13 (Chr5: 132021824, Chr5: 132017404, Chr5: 
132021752) and ORMDL3 (Chr17: 35334712), respec-
tively, were captured by the 450  k array data (Fig.  2c). 
We thus demonstrate that targeted bs-OS-seq is highly 



































































































































































Fig. 2 CpG methylation profiling of IL13 and ORMDL3 genes’ islands and shores and comparison of bs-OS-Seq and 450k array in PBMC from 
healthy males. a DNA methylation in 6 kb of CpG islands and shores were profiled using bs-OS-Seq. Negative (un-methylated) and positive (fully 
methylated) reference DNA extracted from whole blood of NA12878 demonstrate consistent quantitativity of the assay. Six PBMC samples from 
six healthy male donors and the reference sample NA12878 show distinct hypomethylation of the CpG island while having varying degree of 
methylation in the CpG sites residing in the shores. b bs-OS-Seq demonstrated 19x and 15x higher resolution of CpG methylation compared to 
450k array data in the PBMC samples in IL13 (268 vs. 14 CpG sites) and ORMDL3 (259 vs. 17 CpG sites) genes, respectively, while reaching concordant 
methylation results in the shared sites. c The 10% most variable CpG sites contained large variation between the PBMC samples from the six healthy 
male donors. CpG sites also covered by the 450 K array assay are highlighted with a green box
Table 1 Correlation scores (Pearson) of the methylation levels 
of common CpG sites analyzed by bs-OS-Seq and 450k arrays for 
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six healthy adults and DNA samples fully methylated 
and un-methylated as positive and negative controls, in 
CpG islands and shores of the genes IL13 and ORMDL3 
(Fig. 2a).
Blood cell populations cluster together based 
on methylation profiling of IL13 and ORMDL3 using 
targeted bs‑OS‑Seq
To investigate the details of the methylation pattern in 
different cell types, we analyzed sorted blood cell popu-
lations (CD4+ T cells, CD8+ T-cells, CD19+ B cells, 
CD14+ monocytes, granulocytes, and neutrophils) and 
PBMCs from six healthy adult males, and whole blood 
from 22 school-aged children. Based on Kruskall–Wal-
lis statistical analysis, 62 and 96 informative CpG sites in 
the IL13 and ORMDL3 genes, respectively, were identi-
fied. Unsupervised clustering of the data obtained by 
bs-OS-seq was able to segregate the samples distinctly 
in subgroups, representing a predominance of lympho-
cytic methylation pattern, myeloid methylation pattern, 
or neither (Fig. 3), even when using data only for the two 
genes IL13 and ORMDL3 separately. This emphasizes the 
importance of available methylation data from sorted cell 
populations that can be used to correct for methylation 
variation in different cell types (Fig.  3a) when analyz-
ing samples from, e.g., PBMCs or whole blood which is 
a commonly used source of DNA. Methylation in IL13 
showed the largest variations in CD4 + and CD8 + cells 
(cluster 1). Also, several CpG sites in ORMDL3 were 
clearly demethylated in CD4 + and CD8 + cells (cluster 1) 
compared with granulocytes (cluster 5) (Fig.  3a). When 
we added information on the three clinical subgroups 
(therapy resistant asthma, controlled asthma, or healthy) 
of the school-aged children, we demonstrated that the 
clustering based on methylation profiling of IL13 and 
ORMDL3 followed the measured cellular composition in 
the whole blood samples (Fig. 3b).
Discussion
In this study, we show that the methylation data for CpG 
sites obtained by bs-OS-seq correlate with the methyla-
tion data present at the 450k array. Our results cross-val-
idated the accuracy of the methods and revealed patterns 
of methylation variation in the targeted genes that could 
not be discovered by established microarray methods. 
Also, we could show that unsupervised clustering with 
dense methylation data result in distinct segregation 
according to cell type, using data available for the two 
studied loci ORMDL3 and IL13, separately in two inde-
pendent materials. Furthermore, we demonstrate that 
the bs-OS-seq method is highly quantitative, and level 
of methylation can be analyzed by measuring the read-
count depth.
The dense data obtained by bs-OS-seq reveals a much 
richer pattern of methylation variation across the stud-
ied loci than is evident in the 450k array data. Our data 
suggest that much of the biologically important variation 
in methylation may remain undisclosed with the array-
based methods. This new sequencing-based method 
would be an important strategy to verify, and increase the 
knowledge and understanding of the methylation pattern 
in loci identified by screening using existing arrays, or 
for targeted studies of candidate loci. When the probes 
are established, the same setup of CpG sites can easily be 
screened for in many samples in parallel, e.g., a number 
of different tissues, longitudinal samples from the same 
individuals or a number of cohorts. Cross-sectional 
methylation associations in children can reflect both 
risk for and effects of disease, and therefore longitudinal 
sampling and methylation analyses is fundamental. This 
high-resolution method would facilitate detailed longitu-
dinal studies of targeted loci to clarify whether identified 
epigenetic changes is a primary or secondary effect. This 
is a problematic issue in the field of epigenetics, which 
can only be solved with longitudinal studies.
In this comparison, we used the 450k array [1], which 
has more recently been replaced with the EPIC array [2]. 
The EPIC covers over 850,000 CpG sites, including more 
than 90% of the CpGs from the 450k and an additional 
413,743 CpGs [2]. It has high reproducibility, reliability 
and higher coverage than the 450k array, but individual 
CpG sites especially those with low variability show a 
much lower correlation between the two arrays [2, 8, 
9]. However, the coverage is still sparse compared to 
targeted bs-OS-seq in each locus. In our analyses, cap-
ture oligos were designed to target altogether 268 and 
259 CpG positions in the IL13 and ORMDL3 genes, 
respectively. For comparison, the resolution provided by 
the well-established 450k arrays is vastly inferior, as it 
includes probes for analyzing only 14 and 17 CpG sites 
in the IL13 and ORMDL3 genes, respectively. Previously 
450k, and now EPIC arrays work well for genome wide 
screening to identify loci of interest. High-resolution 
analyses like bs-OS-seq are rather intended for targeted 
candidate gene analyses, detailed analyses of regions of 
interest identified by screening analyses performed with 
arrays. As the correlation for some individual CpG sites 
is low between the arrays [8–10], and even differ between 
tissues [10], the interpretation of methylation changes 
in specific CpG sites should be performed with caution, 
and independent validation methods, such as bs-OS-seq, 
should be considered.
The most comprehensive, commonly used method 
for assaying methylation genome-wide is bisulfite 
sequencing. Its use is restricted by the high sequencing 
cost, as a quantitative assay of methylation percentage 
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requires deeper than the usual 30X coverage. Two tar-
geted methods, SeqCap Epi [11, 12] and QIAseq (Qia-
gen), suffer from a more complicated laboratory work 
requiring hands-on resources. Bs-OS-seq is simple to 
perform but highly targeted and will require the setup 
for the specific region of interest, increasing the cost 
for small series of samples. The cost of setup will, how-
ever, rapidly get diluted if the assay is intended for large 
series of samples. A comparison of these four methods 
is outlined in Table 2, indicating the effort or cost with 
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Fig. 3 a Clusters of blood cells were identified using bs-OS-Seq profiling of IL13 and ORMDL3. bs-OS-seq was able to cluster different types of 
blood cells distinctly using methylation data available only for the two gene loci separately, emphasizing the importance of available reference 
data sets that can be used to correct for cell type variation in methylation patterns. Sorted blood cell populations (CD4 + T cells, CD8 + T-cells, 
CD19 + B cells, CD14 + monocytes, granulocytes, and neutrophils) and PBMCs from six healthy adult males (adult 1–6), and 22 whole blood 
samples from asthmatic and healthy school-aged children (1–22; healthy, mild asthma, severe asthma) were included. The whole blood samples 
from the children clustered readily in subgroups representing lymphocytic methylation pattern predominance, myeloid methylation pattern 
predominance, and neither. b Childhood asthma cases clustered with specific subgroups following the composition of blood cell types. 
Clustering based on DNA methylation profiling of IL13 and ORMDL3 revealed asthma subgroups that co-clustered with specific blood cell types. 
Subgrouping based on methylation profiles followed cellular composition in the whole blood samples of the school aged children with asthma. 
CD14 +  = CD14 + monocytes, CD19 +  = CD19 + B cells, CD4 +  = CD4 + T cells, CD8 +  = CD8 + T-cells, Gran = granulocytes, Neu = neutrophils, 
PBMC = peripheral blood mononuclear cells, whole_blood = whole blood, leuk = leukocytes, neu = neutrophils, eos = eosinophils, 
lymf = lymphocytes, mono = monocytes
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DNA methylation as an epigenetic marker has 
gained popularity to explain functional variation at 
loci implicated in diseases with genetic and environ-
mental components. An important disease with such 
characteristics is asthma, where several loci have been 
robustly replicated and are thus interesting targets to 
understand the variation of methylation as a factor pos-
sibly contributing to pathogenesis (Reviewed in [13]). 
Several loci have shown methylation differences asso-
ciated with childhood asthma [14–16], and a recent 
meta-analysis showed that asthma-related differential 
methylation in blood in children was also replicated 
in eosinophils and respiratory epithelium [17]. Impor-
tantly, methylation differences involved in response 
to maternal smoking during pregnancy [18, 19] or 
prenatal exposure to air pollution [20, 21] have been 
identified, indicating a possible connection between 
environment and health through DNA methylation.
Asthma is a multifactorial disease, and both genetic 
and environmental factors are of importance [22, 23]. 
The most replicated and significant asthma locus, espe-
cially for childhood asthma, is located on chromosome 
17q12-21 and contains a cluster of genes, among them 
ORMDL3 reviewed in [24].  ORMDL3 seems to have 
pleiotropic effects during cellular inflammation, con-
sistent with its substantial genetic influence on child-
hood asthma [25, 26]. In addition, possible explanations 
to a connection to rhinovirus infection have been sug-
gested [26, 27]. However, the definite role of ORMDL3 
in the pathogenesis of asthma remains unclear and 
needs further analyses. DNA methylation plays an 
important role in ORMDL3-mediated increased 
cytokine levels [25]. We have previously shown an 
association between asthma and differential methyla-
tion of ORMDL3  from peripheral blood leukocytes in 
asthmatic children from the Swedish Search Study, 
and methylation levels at specific sites correlated with 
gene expression [5]. In the same study [5], we could 
show that the decreased DNA methylation levels in the 
CpG island shore of ORMDL3 was mainly seen in the 
CD8+ T-cells, as is confirmed by bs-OS seq in the same 
DNA samples in this study.
Specific methylation profiles in the IL13 locus have 
been shown in airway epithelium associated with atopy 
and atopic asthma in children [28], as well as nasal epi-
thelia [29] and blood [14].
Our cohort of school-aged asthmatic children was 
too small to contribute to further understanding of the 
importance of methylation in the ORMDL3 or IL13 locus 
by high-resolution analyses, but the amount of CpG sites 
with varying methylation levels illustrates the potential 
of detailed methylation analyses in these loci, most likely 
resulting in additional biological understanding. In addi-
tion, the detailed methylation profiles identified by bs-
OS-seq support our previous findings [5] as the largest 
variations are seen in the lymphoid lineage, supporting 
that those cell populations may be functionally relevant 
for the role of these genes in the asthma pathogenesis. 
Despite a huge effort to understand both genetics and 
epigenetics in asthma data are not conclusive. The major-
ity of the epigenetic studies have been based on array 
data, which has resulted in further understanding for a 
number of diseases. However, the connection of methyla-
tion patterns in relation to health and disease is still not 
clear, and one of the reasons might well be this lack of 
information.
Conclusions
In summary, we have developed a novel, cost-efficient 
and quantitative method for assessing DNA methylation 
at high density in selected genomic regions, based on 
bisulfite conversion, target capture, and deep sequencing. 
Our data show vastly increased information content and 
uncover methylation variation not detected by commonly 
used array methods with lower probe density. We show 
that methylation information from even one single gene, 
but provided at high resolution, contains enough meth-
ylation variation to delineate the main white blood cell 
lineages. In addition, we confirm our previous data [5] 
that decreased DNA methylation levels in the CpG island 
shore of ORMDL3 was mainly seen in CD8 + T-cells. We 
conclude that high-resolution methylation studies can 
yield clinically important information at selected spe-
cific loci missed by array-based methods, with potential 
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implications for future studies of DNA methylation-dis-
ease associations.
Materials and methods
To compare the new Bs-OS-seq method with the estab-
lished Illumina 450k arrays, we analyzed 62 blood sam-
ples with Bs-OS-seq that had previously been analyzed 
on Illumina 450k arrays [4]. Thirty-nine of these samples 
were six sorted blood cell populations (CD4+ T cells, 
CD8+ T-cells, CD19+ B cells, CD14+ monocytes, gran-
ulocytes, and neutrophils) and PBMCs from six healthy 
adult males, and 22 were whole blood samples from 15 
asthmatic and 7 healthy school-aged children.
Study participants and collection of blood samples
Healthy adult males
Peripheral blood (450 ml) was collected from six healthy 
adult male blood donors, age 38.6 ± 13.6 years recruited 
within the MALF study [7] as described elsewhere [4]. 
Briefly, isolated peripheral blood mononuclear cells 
(PBMC), CD4+ T cells, CD8+ T-cells, CD19+ B cells, 
CD14+ monocytes, granulocytes, and neutrophils were 
used in this study. PBMC and granulocytes were iso-
lated using Ficoll-Paque PlusTM (GE Healthcare, Swe-
den). Magnetic-activated cell sorting (MACS, Miltenyi 
Biotech, Germany) was used to obtain T cells, B cells, 
monocytes, and from the PBMCs and neutrophils from 
the granulocyte containing pellet. Cell purities were con-
trolled by fluorescence activated cell sorting (FACS) [4].
School‑aged children with asthma and age‑matched 
healthy controls
The nationwide study on problematic severe asthma in 
Sweden is an observational, multicenter case–control 
investigation in which school-aged children with prob-
lematic severe asthma were compared to age-matched 
peers with controlled persistent asthma [30]. All patients 
were required to have been without airway infections or 
exacerbations of their asthma during a 2-week period 
prior to examination. Details concerning the inclusion 
criteria can be found elsewhere [30]. The sample set used 
in this study consisted of a subgroup of 8 children with 
therapy resistant asthma, which was defined as having 
an insufficient asthma control despite daily inhalation 
of high doses corticosteroids (≥ 800  μg budesonide or 
equivalent) in combination with long-acting beta 2 ago-
nists and/or leukotriene receptor antagonists, no identi-
fiable aggravating environmental exposures (tobacco or 
allergens) and treatment of symptomatic rhinitis. In addi-
tion, 7 children with controlled asthma (defined as chil-
dren having an acceptable asthma control with a low to 
moderate dose of inhaled corticosteroids (< 400 μg bude-
sonide or equivalent) were included. Finally, 7 healthy 
children were recruited at Astrid Lindgren Children’s 
Hospital, Stockholm, Sweden, among children admit-
ted for elective surgical procedures unrelated to asthma. 
The basic characteristics of the children are presented in 
Table 3. Following application of local anesthesia (EMLA 
cream, Astra Zeneca, Sweden), samples of venous blood 
were collected in EDTA test tubes and a white blood cell 
count (leukocytes, neutrophils, eosinophils, lympho-
cytes, monocytes) were performed according to the cur-
rent clinical method at the local department of clinical 
chemistry at each participating clinic.
DNA methylation analyses using Illumina 450 bead chip 
technology
DNA was extracted from PBMC, and the separated cell 
populations from the healthy adults and from whole 
blood in the Swedish search participants. For each sam-
ple, 500 ng of genomic DNA was bisulfite converted with 
the EZ-96 DNA Methylation Kit (Zymo Research Cor-
poration, USA) according to the manufacturer’s instruc-
tions. Array-based-specific DNA methylation analysis 
was performed with the Infinium Human Methylation 
450 K bead chip technology (Illumina, USA) as previously 
Table 3 Basic characteristics of the Swedish Search study
Severe asthma Controlled asthma Healthy controls
Subjects n 8 7 7
Age, years mean (range) 14.7 (9.8–18.6) 14.1 (9.8–17.5) 12.5 (7.2–15.2)
Female/male n 3/5 5/2 1/6
Eosinophils  109 ×  L−1 mean (range) 0.30 (0–0.5) 0.23 (0–0.4) 0.26 (0–0.9)
Neutrophils  109 ×  L−1 mean (range) 3.8 (2.1–5.9) 2.7 (1.7–3.7) 2.9 (2.3–3.7)
Leukocytes  109 ×  L−1 mean (range) 6.8 (4.1–9.5) 6.37 (4.7–9) 5.79 (5–6.8)
Lymphocytes
109 ×  L−1 mean (range)
2.3 (1.6–3.6) 2.83 (2.1–4.3) 2.10 (1.6–2.9)
Monocytes
109 ×  L−1 mean (range)
0.44 (0.3–0.7) 0.57 (0.3–1.1) 0.44 (0.3–0.6)
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described [4, 5]. Briefly, bisulfite-treated genomic DNA 
was whole-genome amplified, hybridized to Human-
Methylation450 BeadChips (Illumina) and scanned using 
the Illumina iScan at the Mutation Analysis Core Facility 
(MAF) or Bioinformatics and Expression Analysis Core 
Facility (BEA) at Karolinska Institutet. The intensity of 
the images was extracted with the GenomeStudio Meth-
ylation Software Module (v 1.9.0, Illumina).
DNA methylation analyses using Bisulfite 
Oligonucleotide‑selective sequencing (Bs‑OS‑seq)
Preparation of bisulfite converted sequencing libraries
We used golden-standard reference DNA extracted from 
whole blood of NA12878 (Coriell, NJ, USA) as a control 
samples in methylation experiments. Before conver-
sion, NA12878 was treated using CpG Methyltransferase 
(M.SssI) (NEB, Ipswich, MA) and whole-genome 
amplification using REPLI-g mini Kit (Qiagen, Hilden, 
Germany) to prepare positive and negative controls, 
respectively. 600  ng of genomic DNA from NA12878 
reference and healthy adult males, and school-aged chil-
dren were converted using the bisulfite method EpiTect 
Fast DNA bisulfite kit (Qiagen). DNA was fragmented 
and denatured during conversion. After conversion, 
whole-genome amplification method, EpiTect Whole 
Bisulfitome Kit (Qiagen) was used for second-strand syn-
thesis and to increase DNA yield. Sequencing libraries 
were generated through end repair, A-tailing and adapter 
ligation using NEBNext Ultra library kit (NEB). Cus-
tom OS-Seq adapters were used in the adapter ligation. 
After library preparation and clean-up, libraries were 
amplified using 25 cycles of PCR and EpiMark Taq poly-
merase (NEB). Amplified libraries were purified using 
1 × AMPure XP beads (Beckman Coulter, Brea, CA).
Designing and creating OS‑Seq primer‑probes 
and sequencing
Target-specific OS-Seq primer-probes were designed 
to capture CpG islands and shores of the ORMDL3 and 
IL13 genes (hg19 was used as a reference for obtain-
ing sequences and gene annotations). CpG islands and 
shores were defined as genomic regions of 3  kb up- 
and downstream from the CpG islands. The genomic 
regions encompassing CpG islands and shores of IL13 
and ORMDL3 were used as targets when designing the 
primer–probe sequences. Primer–probe design algo-
rithm was optimized for hybridization efficiency and to 
minimize secondary structures and hairpin looping. The 
specificity of the target capture was ensured by requiring 
unambiguous mapping of the probe sequences. Optimal 
sequence length was determined based on estimated 
DNA melting temperature. 35–50 base sequences were 
tiled across the target regions. Altogether, we designed 
130 primer probes for IL13 (64 forward strand and 66 
reverse strand and 129 primer probes for ORMDL3 (64 
forward strand and 65 reverse strand) (Additional file 2: 
Table  1). For capturing bisulfite converted DNA, Cs in 
the designed sequences were modified to Ts and Cs in the 
CpG sites were modified to Ys (corresponding either C 
or T). Target-specific oligonucleotides were synthesized 
and re-suspended in 1 M concentration (Integrated DNA 
Technologies, Coralville, IA). Sequencing libraries were 
sequenced using MiSeq Sequencing System (Illumina, 
San Diego, CA) using modified OS-Seq protocol [31, 32]. 
Paired-end sequencing (150-by-150) was applied (Fig. 1).
Primary data analysis
BCL2 to Fastq conversion of the sequence reads was per-
formed using CASAVA software (version 1.8; Illumina). 
Demultiplexing was carried out using custom algorithm 
(Blueprint Genetics, Helsinki, Finland). The BISMARK 
software (version 0.10.0 [33]) performs alignment to 
four alternative reference genomes corresponding to all 
potential conversion states. The software utilizes Bowtie 
to align bisulfite conversed sequencing data from read 1 
using parameter settings selected to maximize mapping 
efficiency. In addition, the software calls the methyla-
tion status of cytosines in the context of CpG. As the last 
step, the BISMARK algorithm estimates the proportion 
of methylated and un-methylated reads at each CpG site 
and reports it as a percentage of methylation in the sam-
ple in a BED-graph format (https:// genome. ucsc. edu/ 
golde nPath/ help/ bedgr aph. html).
Methylation profiling
The BED-graph files were imported and visualized in the 
genomic context using Integrative Genome Viewer [34]. 
Additionally, BED tracks for gene models, primer–probe 
sequences and target definitions were imported for ref-
erence. Methylation profiles of 6 healthy adult males and 
school-aged children were compared.
Comparison of bs‑OS‑Seq and 450k array data
Agreement in measured methylation levels between the 
two methods was assessed by computing pair-wise cor-
relations (Pearson) across all sites where the methods 
had overlapping measurements. A line representing the 
best fit through the data points was added to the scatter 
plot through linear regression. The Heatmap 3 package 
(version 1.1.1), run in the R statistical computing envi-
ronment (version 3.2) was applied to generate un-scaled 
2-dimensional hierarchical clustering of bs-OS-Seq and 
450k array data. Segregation patterns were assessed for 
the CpG sites where data were available for both tech-
nologies and the most varying sites in the bs-OS-Seq data 
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that were selected by identifying the 10% with highest 
coefficient of variability (CV) across all samples.
Comparison of bs‑OS‑Seq patterns across different blood cell 
populations
The Heatmap 3 package (version 1.1.1), run in the R sta-
tistical computing environment (version 3.2) was applied 
to generate un-scaled 2-dimentional hierarchical cluster-
ing of bs-OS-Seq methylation profiling data across whole 
blood from 22 school-aged children and six sorted cell 
population samples and PBMCs from six healthy male 
donors. In order to focus on most informative portion of 
the data, a Kruskall–Wallis statistical test was performed 
to include statistically significantly (p < 0.01) differing 
CpG sites.
Clustering of asthma cases and comparison with blood cell 
population prevalence
Asthma cases co-segregated within subgroups based on 
bs-OS-Seq analysis. Cellular composition of different 
blood cell populations in the whole blood samples col-
lected within the Swedish Search cohort was analyzed 
according to the current clinical method at the local 
department of clinical chemistry at each participating 
clinic.
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